1716P Do proton pump inhibitors affect the survival outcomes and safety in colorectal cancer patients treated with regorafenib? A single center and real-life experience

Abstract

Cancer patients receive proton pump inhibitors (PPIs) to protect against the adverse gastric effects of anti-cancer medications. With this regard, PPIs are frequently prescribed to cancer patients irrespective of their indications. However, alterations in gastric pH levels may affect the absorbtion of oral anti-cancer drugs.